FrancophonIA/ELRC3.0 huggingface dataset:
English: Transient, generally asymptomatic, increase in blood pressure may occur in patients receiving hydroxocobalamin.
Croatian: Kod bolesnika koji primaju hidroksokobalamin može se javiti prolazni, općenito asimptomatski, porast krvnog tlaka.
English: Decrease in the percentage of lymphocytes.
Croatian: Pad postotka limfocita.
English: Mean corpuscular haemoglobin (MCH) Mean corpuscular haemoglobin concentration (MCHC)
Croatian: Hematologija eritrociti hematokrit srednja vrijednost korpuskularnog volumena (MCV) leukociti limfociti monociti eozinofili neutrofili trombociti hemoglobin (Hb) srednja vrijednost korpuskularnog hemoglobina (MCH) srednja vrijednost koncentracije hemoglobina u eritrocitima (MCHC)
English: • swelling of ankles
Croatian: • oticanje gležnjeva
English: Hydrochloric acid (for pH-adjustment)
Croatian: 6.1 Popis pomoćnih tvari kloridna kiselina (za podešavanje pH) 6.2 Inkompatibilnosti
English: • difficulty in swallowing.
Croatian: • poteškoće pri gutanju.
English: These side effects can be serious in more than 1 in 10 people.
Croatian: Te nuspojave mogu biti ozbiljne u više od 1 na 10 osoba.
English: The patient usually receives 3 infusions within one week.
Croatian: Bolesnik obično prima tri infuzije u razdoblju od jednog tjedna.
English: This overview was last updated in 03-2018.
Croatian: Ovaj pregled informacija posljednji je put ažuriran u 3-2018.
English: If the cancer responds to initial treatment, the patient may receive further ‘consolidation' treatment to keep the cancer from coming back.
Croatian: Ako rak reagira na početno liječenje, bolesnik može dobiti dodatno „konsolidacijsko” liječenje kako bi se spriječilo ponovno pojavljivanje raka.
English: Although some side effects with Mylotarg can be serious, they were considered acceptable in light of the severity of the patients' condition.
Croatian: Iako neke nuspojave lijeka Mylotarg mogu biti ozbiljne, smatraju se prihvatljivima s obzirom na ozbiljnost stanja bolesnika.
English: Further information on Mylotarg can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Više informacija o lijeku Mylotarg možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Mylotarg and what is it used for?
Croatian: Što je Mylotarg i za što se koristi?
English: Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Više informacija o statusu lijeka za rijetke bolesti možete pronaći ovdje: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The patient is also given medicines to help prevent reactions such as reddening of the skin, chills and fever.
Croatian: Bolesniku se također daju lijekovi koji pomažu u sprječavanju reakcija kao što su crvenilo kože, zimica i vrućica.
English: What measures are being taken to ensure the safe and effective use of Mylotarg?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Mylotarg?
English: Side effects reported with Mylotarg are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Mylotarg pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mylotarg have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Mylotarg nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Other information about Mylotarg
Croatian: Ostale informacije o lijeku Mylotarg
English: Mylotarg infusions must be given in a place (such as a hospital) where the patient can be resuscitated if there are severe reactions.
Croatian: Infuzije lijeka Mylotarg moraju se primjenjivati u okruženju (kao što je bolnica) u kojem se u slučaju teških reakcija može provesti reanimacija bolesnika.
English: Why is Mylotarg authorised in the EU?
Croatian: Zašto je lijek Mylotarg odobren u EU-u?
English: As for all medicines, data on the use of Mylotarg are continuously monitored.
Croatian: Kao za sve lijekove, podatci o primjeni lijeka Mylotarg kontinuirano se prate.
English: The most common side effects with Mylotarg when given in combination with daunorubicin and cytarabine (which may affect more than 3 in 10 people) are bleeding and severe infections.
Croatian: Najčešće nuspojave lijeka Mylotarg kada se primjenjuje u kombinaciji s daunorubicinom i citarabinom (koje se mogu javiti u više od 3 na 10 osoba) jesu krvarenje i teške infekcije.
English: The European Medicines Agency decided that Mylotarg's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Mylotarg nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: Other serious side effects with the combination therapy are liver disease, including veno-occlusive disease (a liver injury), and tumour lysis syndrome (a complication due to the breakdown of cancer cells).
Croatian: Druge ozbiljne nuspojave kombinacijske terapije jesu bolesti jetre, uključujući venookluzivnu bolest (oštećenje jetre) i sindrom lize tumora (komplikacija uslijed raspada stanica raka).
English: In patients receiving Mylotarg in combination with daunorubicin and cytarabine, it took an average of 17.3 months until the treatment failed, the cancer came back or the patient died, compared with 9.5 months in patients receiving a combination of only daunorubicin and cytarabine.
Croatian: U bolesnika koji su primali lijek Mylotarg u kombinaciji s daunorubicinom i citarabinom u prosjeku je proteklo 17,3 mjeseci prije no što je terapija postala neuspješna, ponovno se pojavio rak ili je bolesnik umro, u usporedbi s 9,5 mjeseci u bolesnika koji su primali samo kombinaciju daunorubicina i citarabina.
English: AML is rare, and Mylotarg was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 October 2000.
Croatian: AML je rijetka bolest, a Mylotarg je dobio status „lijeka za liječenje rijetkih bolesti” 18. listopada 2000.
English: For more information about using Mylotarg, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Mylotarg, pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: When the antibody attaches to CD33 on leukaemia cells, the cells absorb the antibody, as well as the cytotoxic substance that it is attached to.
Croatian: Kada se protutijelo veže na CD33 na leukemijskim stanicama, one apsorbiraju protutijelo kao i citotoksičnu tvar na koju je protutijelo vezano.
English: The calicheamicin then breaks up the cells' DNA, eventually killing the cells.
Croatian: Kalikeamicin zatim uzrokuje lomove DNK stanica i naposljetku ih ubija.
English: What are the risks associated with Mylotarg?
Croatian: Koji su rizici povezani s lijekom Mylotarg?
English: It is not used for a type of AML called acute promyelocytic leukaemia (APL).
Croatian: Lijek se ne primjenjuje za liječenje vrste AML-a naziva akutna promijelocitna leukemija (APL).
English: It is used in combination with daunorubicin and cytarabine (other cancer medicines).
Croatian: Lijek se primjenjuje u kombinaciji s daunorubicinom i citarabinom (drugi lijekovi protiv raka).
English: Mylotarg is given as an infusion into a vein lasting 2 hours.
Croatian: Mylotarg se primjenjuje intravenskom infuzijom tijekom dva sata.
English: Mylotarg is used in patients with a protein called CD33 on their cancer cells (which is the case in most patients with AML).
Croatian: Mylotarg se primjenjuje u bolesnika koji na površini stanica raka imaju bjelančevinu naziva CD33 (što je slučaj u većine bolesnika s AML-om).
English: A main study in 271 patients with AML has shown that adding Mylotarg to daunorubicin and cytarabine can prolong the time patients live without their cancer coming back by around 8 months.
Croatian: Glavno ispitivanje na 271 bolesniku s AML-om pokazalo je da dodavanje lijeka Mylotarg daunorubicinu i citarabinu može produljiti razdoblje tijekom kojeg bolesnici žive bez ponovnog pojavljivanja raka za otprilike osam mjeseci.
English: Mylotarg is a medicine used to treat a blood cancer called acute myeloid leukaemia (AML) in patients aged 15 years and above who are newly diagnosed and have not tried other treatments.
Croatian: Mylotarg je lijek koji se primjenjuje za liječenje raka krvi naziva akutna mijeloična leukemija (AML) u novodijagnosticiranih bolesnika u dobi od 15 i više godina koji nisu primili druge oblike liječenja.
English: The patient will also be given two other medicines: daunorubicin and cytarabine.
Croatian: Bolesnik također prima druga dva lijeka, daunorubicin i citarabin.
English: Mylotarg can only be obtained with a prescription.
Croatian: Lijek Mylotarg izdaje se samo na liječnički recept.
English: How does Mylotarg work?
Croatian: Kako djeluje Mylotarg?
English: An overview of Mylotarg and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Mylotarg i razlozi njegova odobrenja u EU-u
English: Inside the cells, the cytotoxic substance, which is called calicheamicin, is released.
Croatian: Unutar stanica oslobađa se citotoksična tvar naziva kalikeamicin.
English: Mylotarg contains the active substance gemtuzumab ozogamicin.
Croatian: Mylotarg sadrži djelatnu tvar gemtuzumab ozogamicin.
English: The monoclonal antibody part (gemtuzumab) has been designed to attach to CD33.
Croatian: Monoklonsko protutijelo (gemtuzumab) namijenjeno je vezivanju na CD33.
English: How is Mylotarg used?
Croatian: Kako se Mylotarg koristi?
English: What benefits of Mylotarg have been shown in studies?
Croatian: Koje su koristi od lijeka Mylotarg utvrđene u ispitivanjima?
English: The active substance in Mylotarg, gemtuzumab ozogamicin, consists of two parts: a cytotoxic (cellkilling) substance and a monoclonal antibody (a type of protein).
Croatian: Djelatna tvar u lijeku Mylotarg, gemtuzumab ozogamicin, sastoji se od dvaju dijelova: citotoksične tvari (koja ubija stanice) i monoklonskog protutijela (vrsta bjelančevine).
English: For the full list of side effects and restrictions with Mylotarg, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Mylotarg potražite u uputi o lijeku.
English: Mylotarg, given in combination with daunorubicin and cytarabine, has been shown to prolong the time patients lived before the cancer came back by up to 8 months.
Croatian: Utvrđeno je da primjena lijeka Mylotarg u kombinaciji s daunorubicinom i citarabinom produljuje razdoblje tijekom kojeg bolesnici žive bez ponovnog pojavljivanja raka do osam mjeseci.
English: Cardboard box containing either 1 or 6 bottles.
Croatian: Kartonska kutija koja sadrži 1 ili 6 boca.
English: Advice to doctors:
Croatian: Savjet liječnicima:
English: • Avoid contact by mouth.
Croatian: • Izbjegavajte dodir s ustima.
English: Date of first authorisation: 21/06/2016
Croatian: Datum prvog odobrenja: 21/06/2016.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/ .
Croatian: Podrobnije informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web stranicama Europske agencije za lijekove http://www.ema.europa.eu/.
English: Appropriate treatment should readily be instituted.
Croatian: Odmah se mora primijeniti odgovarajuće liječenje.
English: None known.
Croatian: Nizu poznate.
English: The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36% and the MAC in cats 3.1%.
Croatian: Minimalna alveolarna koncentracija (MAC) sevoflurana u pasa je 2,36%, MAC u mačaka je 3,1%.
English: Interaction with other veterinary medicinal products and other forms of interaction
Croatian: Interakcije s drugim veterinarsko-medicinskim proizvodima i drugi oblici interakcija
English: Pharmacotherapeutic group: inhalation anaesthetic, ATCvet code: QN 01AB08
Croatian: FARMAKOLOŠKA SVOJSTVA Farmakoterapijska grupa: inhalacijski anestetici, ATKvet kod: QN 01AB08
English: 250 ml Type III amber glass bottle with a yellow collar on the neck, sealed with a poly-seal cap, and secured with PET film.
Croatian: Staklena boca od 250 ml, Tip III amber, sa žutim ovratnik na vratu, zapečaćena s poli-kapom i osigurana PET filmom.
English: Once formed, HFIP is rapidly conjugated with glucuronic acid and eliminated as a urinary metabolite.
Croatian: Kad se jednom stvori, HFIP se brzo konjugira s glukuronskom kiselinom i eliminira kao metabolit mokraćom.
English: • Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.
Croatian: • Osigurajte da su operacijske dvorane i prostorije za oporavak životinja opremljene prikladnim sustavom ventilacije i pročišćavanja, kako bi se spriječilo nakupljanje para anestetika.
English: In order to minimise exposure to sevoflurane vapour, the following recommendations are made:
Croatian: Da bi se smanjila izloženost parama sevoflurana, sastavljene su sljedeće preporuke:
English: 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
Croatian: 1,1,3,3,3-pentafluoro-2-(fluorometoksi) propen (C4H2F6O), također poznat pod nazivom Spoj A, nastaje interakcijom sevoflurana s mješavinom kalcijevog, natrijevog i kalijevog hidroksida ili barijevog hidroksida.
English: In case of accidental contact with the skin, wash the affected area with abundant water.
Croatian: U slučaju nehotičnog dodira s kožom, isperite zahvaćeno područje obilnom količinom vode.
English: Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs and cats.
Croatian: Respiratorna depresija može dovesti do respiratorne acidoze i respiratornog aresta (pri koncentracijama sevoflurana od 2,0 MAC i višima) u pasa i mačaka sa spontanim disanjem.
English: Alpha-2-agonists cause bradycardia which may occur when they are used with sevoflurane.
Croatian: Alfa-2-agonisti uzrokuju bradikardiju može nastati kad se koriste sa sevofluranom.
English: In cats sevoflurane has been shown to exert some neuromuscular blocking effect, but this is only apparent at high doses.
Croatian: Kod mačaka je dokazano da sevofluran ima neki neuromuskularni blokirajući učinak, ali to je vidljivo samo pri visokim dozama.
English: In the dog, sevoflurane may increase intracranial pressure at concentrations of 2.0 MAC and above under normal partial pressures of carbon dioxide (normocapnia), but intracranial pressure has been shown to remain within normal range at sevoflurane concentrations of up to 1.5 MAC if hypocapnia is induced by hyperventilation.
Croatian: U pasa Sevofluran može povećati intrakranijalni tlak pri koncentracijama od 2,0 MAC i višima uz normalni parcijalni tlak ugljičnog dioksida (normokapnija), ali pokazalo se da intrakranijalni tlak ostaje unutar normalnog raspona kad je koncentracija sevoflurana do 1,5 MAC, ako se hipokapnija izaziva hiperventilacijom.
English: D OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
Croatian: OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE U PROMET
English: A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30 °C is 0.63 to 0.69).
Croatian: Potrebno je da samo minimalna količina sevoflurana bude otopljena u krvi prije nego što se postigne ravnoteža između alveolarnog parcijalnog tlaka i arterijskog parcijalnog tlaka, zato što je sevofluran slabo topljiv u krvi (koeficijent raspodjele krv/plin pri temperaturi od 30 °C iznosi 0,63 do 0,69).
English: In dogs, concentrations of sevoflurane below 2.0 MAC result in a small net increase in total liver blood flow.
Croatian: U pasa, koncentracije sevoflurana manje od 2,0 MAC rezultiraju malim neto povećanjem ukupnog protoka krvi kroz jetru.
English: Sevoflurane administration is compatible with the intravenous barbiturates and propofol and in cats alfaxalone and ketamine.
Croatian: Sevofluran je kompatibilan s intravenskim barbituratima i propofolom, a u mačaka s alfaksalonom i ketaminom.
English: Studies in dogs and cats show that anticholinergic premedication is compatible with sevoflurane anaesthesia in dogs and cats.
Croatian: Ispitivanja u pasa i mačaka pokazuju da je premedikacija antikolinergicima kompatibilna s anestezijom sevoflurana u pasa i mačaka.
English: Sevohale contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way.
Croatian: Sevohale ne sadrži stabilizator i ne utječe na kalibraciju i rad ovih isparivača ni na koji način.
English: PB 3
Croatian: Constitución 1. PB 3
English: BN{number}
Croatian: Lot {broj}
English: Do not use this veterinary medicinal product after the expiry date which is stated on the label.
Croatian: Ne primjenjivati ovaj veterinarsko - medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi.
English: Sevohale should be administered via a vaporiser specifically calibrated for use with sevoflurane so that the concentration delivered can be accurately controlled.
Croatian: Sevohale treba primijeniti putem isparivača posebno kalibriranog za uporabu sa sevofluranom, tako da se dostavljena koncentracija može točno kontrolirati.
English: The colour indicator of most CO2 absorbents does not necessarily change as a result of desiccation.
Croatian: Boja indikatora kod većine apsorbera CO2 ne mijenja se nužno kao posljedica sušenja.
English: In common with all volatile agents, sevoflurane may cause hypotension in hypovolaemic animals such as those requiring surgery to repair traumatic injury, and lower doses should be administered in combination with appropriate analgesics.
Croatian: Isto kao i druge hlapljiva tvari, sevofluran može uzrokovati hipotenziju kod hipovolemičnih životinja, kao što su one koje zahtijevaju operaciju zbog traumatskih ozljeda, a niže doze treba davati u kombinaciji s odgovarajućim analgeticima.
English: Bottle label
Croatian: {Etiketa za bočicu }
English: In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.
Croatian: U pasa s ozljedama glave ili drugim stanjima kod kojih postoji rizik od povećanja intrakranijalnog tlaka preporučuje se izazivanje hipokapnije pomoću kontrolirane hiperventilacije kao načina sprječavanja promjene intrakranijalnog tlaka.
English: Sevohale overdose may result in profound respiratory depression.
Croatian: Predoziranje anestetikom Sevohale može izazvati duboku respiratornu depresiju.
English: Intravenous anaesthetics:
Croatian: Intravenski anestetici:
English: Advice to doctors: Maintain a patent airway and give symptomatic and supportive treatment.
Croatian: Savjet liječnicima: Održavati prohodnost dišnih puteva i dati simptomatsku i potpornu terapiju.
English: Since the reaction of carbon dioxide with absorbents is exothermic, this temperature increase will be determined by the quantities of CO2 absorbed, which in turn will depend on fresh gas flow in the anaesthetic circle system, metabolic status of the dog and ventilation.
Croatian: Budući da je reakcija ugljikovog dioksida s apsorberima egzotermička, to povećanje temperature bit će određeno količinom apsorbiranog CO2, što će zauzvrat ovisiti o protoku svježeg plina kroz anestetički kružni sustav, metaboličkom statusu psa i ventilaciji.
English: These concentrations can be expected to produce surgical anaesthesia within 3 to 14 minutes in dogs and within 2 to 3 minutes in cats.
Croatian: Očekuje se da će takve koncentracije izazvati kiruršku anesteziju u roku od 3 do 14 minuta u pasa te unutar 2 - 3 minute u mačaka.
English: PARTICULARS TO APPEAR ON THE INNER PACKAGE
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU
English: If malignant hyperthermia develops, the anaesthetic supply should be interrupted immediately and 100% oxygen administered using fresh anaesthetic hoses and a rebreathing bag.
Croatian: Ako se razvije maligna hipertermija, dostava anestetika mora se odmah prekinuti i primijeniti 100%- tni kisik kroz nove anestetičke cijevi i pomoću balona za povratno udisanje.
English: Maintain a patent airway and give symptomatic and supportive treatment.
Croatian: Održavati prohodnost dišnih puteva i dati simptomatsko i potporno liječenje.
English: For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog, and 6 to 8% sevoflurane with oxygen in the cat.
Croatian: Za uvođenje u anesteziju pomoću maske, udahnute koncentracije sevoflurana od 5-7% s kisikom koji se koriste da bi se inducirala kirurška anestezija u zdravih pasa te 6 - 8% sevoflurana s kisikom u mačaka..
English: In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia.
Croatian: U pasa izloženih koncentraciji sevoflurana od 4% tijekom 3 sata, prosječne vršne koncentracije fluorida primijećene u serumu iznosile su 20,0 ± 4.8 µmol/l nakon 3 sata anestezije.
English: For induction and maintenance of anaesthesia.
Croatian: Za uvođenje u anesteziju i održavanje anestezije.
English: Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Croatian: Anestetički protokoli koji uključuju premedikaciju opijatima, alfa-2-agonistima, benzodiazepinima ili fenotiazinima omogućit će uporabu nižih koncentracija sevoflurana za održavanje anestezije.
English: Sevoflurane has a variable effect on heart rate, which tends to increase from baseline at low MAC and fall back with increasing MAC. Sevoflurane causes systemic vasodilation and produces dose dependent decreases in mean arterial pressure, total peripheral resistance, cardiac output and possibly the strength of myocardial contraction and speed of myocardial relaxation.
Croatian: Sevofluran izaziva sistemsku vazodilataciju i ovisno o dozi izaziva smanjenje prosječnog arterijskog tlaka, ukupne periferne rezistencije, srčanog minutnog volumena i moguće jačine kontrakcije miokarda i brzine relaksacije miokarda.
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Croatian: Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadne materijale dobivene primjenom tih veterinarsko-medicinskih proizvoda treba odlagati u skladu s lokalnim propisima.
English: Long duration, low-flow sevoflurane anaesthesia should be avoided due to the risks of Compound A accumulation.
Croatian: Dugotrajnu anesteziju niskim protokom sevoflurana treba izbjegavati zbog rizika od nakupljanja Spoja A.
English: 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Croatian: 6.6 Posebne mjere opreza prilikom odlaganje neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
English: PACKAGE LEAFLET: Sevohale Inhalation vapour, liquid for dogs and cats, 100% v/v sevoflurane
Croatian: UPUTA O VMP: Sevohale para inhalata, tekućina za pse i mačke, 100% v/v sevofluran